BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260928
DTEND;VALUE=DATE:20261001
DTSTAMP:20260614T052300
CREATED:20260528T115319Z
LAST-MODIFIED:20260528T115319Z
UID:43639-1790553600-1790812799@www.pharmajournalist.com
SUMMARY:7th Genome Editing Therapeutics Summit
DESCRIPTION:The FDA has shown its’ hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly: regulators want genome editing therapies to reach patients. Biopharma is also pushing back with a surge of novel genome editing assets deployed in the last 2 years\, targeting rare and prevalent diseases with scarce treatment options. \n \nBut intent and support alone won’t get these therapies to patients. Developmental\, manufacturing\, and regulatory challenges still stand between the lab and the patients waiting. \nThat’s why the 7th Genome Editing Therapeutics Summit is returning to Boston this September\, as the only industry-focused meeting dedicated to applying breakthrough genome editing tools directly to the therapeutic setting. \nJoin R&D\, preclinical\, translational\, regulatory\, and c-suite leaders to answer one question: how do we maximize the application of genome editing therapies to patients who need them most? \nDon’t miss out on insights from AbbVie\, Bristol Myers Squibb\, Intellia Therapeutics\, Beam Therapeutics\, Sanofi\, and many more on how genome editing can move from a promising therapy to an essential one for patients facing the most genetically complex diseases.   \nWhat’s New in 2026? \nIn 2026\, companies are doubling down on translating cutting-edge genome editing technologies into clinically viable therapies. With the FDA’s new mechanism pathway reshaping strategy\, the decisions made now will determine which assets reach patients. \nAt this year’s summit you will: \n\nDelve into extrahepatic delivery strategies to widen your technology across multiple disease indications\n\n\nLearn from clinical companies building robust IND packages to fast-track development\n\n\nEvaluate immunogenicity and off-targeting case studies to sharpen your therapy’s safety profile\n\nExplore the Brand-New Agenda to Discover: \n\n3 days of content to find the sessions your program needs most\n\n\n50:50 clinical & preclinical speakers to find genome editing talks relevant to your development stage\n\n\n80% Directors\, VPs & C-suite to benchmark your genome editing strategy against the right decision-makers\n\n\n64% in vivo & 36% ex vivo agenda to fit your route of delivery\n\n\n2 brand-new workshops\n\nView the full program here to see the 18+ speaker faculty and full session details: https://ter.li/sda9n7qy
URL:https://www.pharmajournalist.com/event/7th-genome-editing-therapeutics-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260929
DTEND;VALUE=DATE:20261002
DTSTAMP:20260614T052300
CREATED:20260423T154336Z
LAST-MODIFIED:20260427T150843Z
UID:43381-1790640000-1790899199@www.pharmajournalist.com
SUMMARY:10th IPF Summit
DESCRIPTION:10th Anniversary Edition of the IPF Summit – \nSeptember 29 – October 1\, 2026 | Boston\, MA \nFor a decade\, the IPF Summit has been the go-to\, discussion-led forum uniting stakeholders across the pulmonary fibrosis ecosystem. In its 10th anniversary year\, the stakes\, and the opportunity\, have never been higher. \nFollowing a wave of positive Phase III readouts from leading companies including Bristol Myers Squibb\, United Therapeutics\, and Boehringer Ingelheim\, the field has entered a new era of momentum. But with this progress comes increasing complexity. As standards of care evolve and more therapies emerge\, the question is no longer can we develop treatments\, but how to do so smarter\, faster\, and with meaningful differentiation. \nThe 10th IPF Summit is the only end-to-end\, industry-led meeting designed to tackle this challenge head-on. \nBringing together 150+ experts across discovery\, translational science\, and clinical development\, from organizations including Bristol Myers Squibb\, United Therapeutics\, Boehringer Ingelheim\, Pfizer\, Novartis\, AbbVie\, PureTech Health\, Insilico Medicine\, and many more\, the summit offers a uniquely integrated view of the scientific\, clinical\, and strategic decisions shaping the next decade of IPF innovation. \nAcross dedicated content tracks\, dive into emerging biology and novel targets to unlock new therapeutic avenues\, biomarker-driven and translational strategies to generate clearer signals earlier and next-generation clinical trial design and combination approaches to succeed in an increasingly competitive landscape \nNew for 2026 includes a dedicated ILD & PPF Focus Day\, designed to unpack the complexity of fibrotic lung diseases beyond IPF\, alongside an investor panel offering insight into building conviction and demonstrating differentiated value in an evolving funding environment.\nWith 8+ hours of networking in an intentionally intimate setting\, the summit is built for honest\, high-value discussions\, giving you direct access to the people shaping the future of pulmonary fibrosis drug development. \nWhether you’re advancing early discovery\, translating assets into the clinic\, or positioning therapies in a crowded market\, this is where the field aligns on what success now looks like\, and how to achieve it. \nFind out more about the 10th Anniversary Edition of the IPF Summit: https://ter.li/5ny4yhvk
URL:https://www.pharmajournalist.com/event/10th-ipf-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261005
DTEND;VALUE=DATE:20261009
DTSTAMP:20260614T052300
CREATED:20260528T110955Z
LAST-MODIFIED:20260528T110955Z
UID:43630-1791158400-1791503999@www.pharmajournalist.com
SUMMARY:16th World Clinical Biomarkers & Companion Diagnostics Summit
DESCRIPTION:Fueled by surging digital pathology partnerships\, improved MRD sensitivity and high-plex single‑cell and multi‑omic profiling to breakthroughs\, the precision medicine field is evolving rapidly. \nBuilding on this momentum\, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns to Boston this fall\, uniting 850+ senior stakeholders in the common goal of advancing timely\, accessible and affordable precision medicine to patients in need. \nBe the first to access our new event program: https://ter.li/5c0adwgh \nJoin industry-leading peers from biopharma\, diagnostics\, testing labs\, and regulatory bodies\, to unpack fit-for-purpose CDx strategies\, spark new co-development partnerships\, discover cutting-edge genomic sequencing\, pathology\, multi-omic\, single cell and multimodal innovations. \nThis year’s agenda will expand to five dedicated tracks of content to ensure your entire team leave equipped with the tools and insights to tackle the specific challenges facing them at their stage of development. \n\nBiomarker Discovery & Translation\nClinical & CDx Development\nRx-Dx Commercialization & Adoption\nDigital Pathology & Spatial Biomarkers (BRAND-NEW)\nMultimodal & AI‑Enabled Endpoints (BRAND-NEW)\n\nGrasp the opportunity to attend the industry’s leading touchpoint for drug-diagnostic co-development advancement. \nTogether let’s translate promising precision medicine into scalable\, equitable drug-diagnostic therapies for patients across oncology\, neurological\, autoimmune\, rare and chronic diseases. \nSign up today: https://ter.li/0jb66uvu \nRegistration is FREE* for drug developers and researchers.  \n*Subject to terms and conditions visit the website to learn more.
URL:https://www.pharmajournalist.com/event/16th-world-clinical-biomarkers-companion-diagnostics-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261012
DTEND;VALUE=DATE:20261016
DTSTAMP:20260614T052300
CREATED:20260512T103447Z
LAST-MODIFIED:20260512T103447Z
UID:43484-1791763200-1792108799@www.pharmajournalist.com
SUMMARY:17th World ADC San Diego
DESCRIPTION:Returning as the largest and definitive ADC congress\, the 17th World ADC San Diego is THE one-stop bioconjugate shop\, bringing together the global ADC community for an unparalleled amalgamation of case studies\, development trends and networking opportunities to forge ADC innovation into differentiated\, early-line patient outcomes. \nWith 7 streams of end-to-end ADC content across Discovery Chemistry\, Discovery Biology\, Preclinical\, Translational Medicine\, Clinical Lessons\, Process & Analytical Development\, and Manufacturing & Supply\, all ADC innovation will be in the spotlight for an unmissable week of data and insights to de-risk future ADC development and push ADCs into earlier line oncology treatments. \nUniting 1\,300 industry senior enthusiasts from biopharma\, innovative start-ups\, leading service providers and academic\, physician and regulator KOLs\, World ADC San Diego is the place to discuss\, debate and advance the future of ADC development. \nFeaturing 170+ senior presenters\, a snapshot of the 2026 speaker faculty includes: \n\nSuzanne Edavettal\, Vice President\, Research & Head\, Protein Therapeutics\, Amgen\nVinod Bulusu\, Executive Director\, Product Stewardship Lead\, AstraZeneca\nGiorgia Vicentini\, Vice President\, Global Program Lead\, Oncology\, Bristol Myers Squibb\nRonald Fleming\, Executive Director\, Clinical Development\, Daiichi Sankyo\nGail Lewis\, Distinguished Scientist\, Discovery Oncology\, Genentech\nMin Hu\, Senior Vice President\, Discovery\, Innovent Biologics\nBob Lutz\, Chief Scientific Officer\, Iksuda Therapeutics\nJeffrey Settleman\, Chief Scientific Officer\, Oncology R&D\, Pfizer\nDominik Schumacher\, Chief Executive Officer\, Tubulis\nRita Nanda\, Associate Professor\, Medicine & Director\, Breast Oncology\, Section of Hematology/Oncology\, University of Chicago\n\nView the full list of speaking companies: https://ter.li/xsz013cs \nIf you want to stay competitive in the field\, you cannot miss World ADC San Diego to de-risk future ADC development and push ADCs to earlier-line oncology treatments.
URL:https://www.pharmajournalist.com/event/17th-world-adc-san-diego/
LOCATION:Town & Country San Diego\, 500 Hotel Circle\, North San Diego\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261030
DTSTAMP:20260614T052300
CREATED:20260609T083754Z
LAST-MODIFIED:20260609T083754Z
UID:43704-1792972800-1793318399@www.pharmajournalist.com
SUMMARY:9th TPD & Induced Proximity Summit
DESCRIPTION:After a decade of innovation\, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026\, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already\, the headwinds are reversing with $15B worth of upfront deals involving TPD candidates and companies in 2026 alone. \nHowever\, following the risk-averse funding environment of 2025\, continued positive clinical data is key to regaining investor confidence and pharma interest. That’s why the 9th TPD & Induced Proximity Summit is returning as the globe’s definitive forum to help you gain that ever-important clinical validation. As the world’s largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development\, it is designed to help you discover the best novel targets\, optimize your degrader profile\, and accelerate your pipelines to the clinic and beyond. \nView the full event guide.
URL:https://www.pharmajournalist.com/event/9th-tpd-induced-proximity-summit/
LOCATION:The Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR